Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | not detected in single-cell data | 0.00 |
| chemistry Open Targets | compounds already reach it: ebdarokimab, guselkumab, mirikizumab +5 | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 6 Parkinson's papers of 1,214 | 0.74 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7927
Sealed predictions
- IL12B in dopamine neurons, braak+0.47 (p 0.197) → -0.52 (p 0.150)receipt 7934
Swarm cases
receipt 7934: IL12B in dopamine neurons, braak
- power
- full sample -0.15 (p 0.555, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.10 (p 0.690, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.498, n 18). could be the mix.
- skeptic
- leave-one-out range -0.29 to -0.06, sign flips 0; without severely affected donors -0.15 (p 0.555, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL12B in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts